U.S. markets open in 8 hours 22 minutes
  • S&P Futures

    3,881.50
    -17.25 (-0.44%)
     
  • Dow Futures

    31,390.00
    -119.00 (-0.38%)
     
  • Nasdaq Futures

    13,223.00
    -56.75 (-0.43%)
     
  • Russell 2000 Futures

    2,258.60
    -16.20 (-0.71%)
     
  • Crude Oil

    59.84
    -0.80 (-1.32%)
     
  • Gold

    1,713.90
    -9.10 (-0.53%)
     
  • Silver

    26.08
    -0.60 (-2.24%)
     
  • EUR/USD

    1.2026
    -0.0033 (-0.28%)
     
  • 10-Yr Bond

    1.4460
    0.0000 (0.00%)
     
  • Vix

    23.35
    -4.60 (-16.46%)
     
  • GBP/USD

    1.3885
    -0.0035 (-0.25%)
     
  • USD/JPY

    106.8130
    +0.0830 (+0.08%)
     
  • BTC-USD

    48,601.31
    +2,154.73 (+4.64%)
     
  • CMC Crypto 200

    974.72
    -11.93 (-1.21%)
     
  • FTSE 100

    6,588.53
    +105.10 (+1.62%)
     
  • Nikkei 225

    29,412.67
    -250.83 (-0.85%)
     

Silk Road Medical to Report Fourth Quarter and Full Year 2020 Financial Results on March 1, 2021

  • Oops!
    Something went wrong.
    Please try again later.
Silk Road Medical
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

SUNNYVALE, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results for the fourth quarter and full year 2020 after market close on Monday, March 1, 2021. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by dialing (844) 883-3861 for domestic callers or (574) 990-9820 for international callers, using conference ID: 3554549. A live and archived webcast of the event will be available at https://investors.silkroadmed.com/.

About Silk Road Medical
Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact. The company’s flagship procedure, TransCarotid Artery Revascularization (TCAR), is clinically proven to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter, LinkedIn and Facebook.

Investor Contact:
Lynn Lewis or Caroline Paul
Gilmartin Group
investors@silkroadmed.com